

**South East London Area Prescribing Committee  
Formulary recommendation**

<b>Reference:</b>	<b>108</b>
<b>Intervention:</b>	<b>Latanoprost 50 micrograms /mL with timolol 5 mg /mL preservative free unit dose eye drops (Fixapost<sup>®</sup>) for the treatment of elevated intraocular pressure in adults with open angle glaucoma and ocular hypertension</b> (Latanoprost is a prostaglandin analogue [PGA] which lowers the pressure in the eye)
<b>Date of Decision:</b>	<b>July 2019</b>
<b>Date of Issue:</b>	<b>August 2019</b>
<b>Recommendation:</b>	<b>Amber 2 – initiation and first prescription supplied by the ophthalmology team</b>
<b>Further Information</b>	<ul style="list-style-type: none"> <li>• Latanoprost 50 micrograms /mL with timolol 5 mg /mL preservative free unit dose eye drops (Fixapost<sup>®</sup>) is accepted for use in South East London within its licensed indication: <ul style="list-style-type: none"> <li>– Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.</li> </ul> </li> <li>• Use is accepted in line with the local pathway for managing Chronic Open Angle Glaucoma and Ocular Hypertension, which is being updated to reflect this formulary recommendation. Use of this preparation will be restricted as follows: <ul style="list-style-type: none"> <li>(i) Preservative free preparations are reserved for patients with a true preservative allergy and/or who have evidence of epithelial toxicity and/or severe dry eyes. <b>Note:</b> This will be based on clinical opinion of the initiating specialist.</li> <li>(ii) Where a preservative free prostaglandin is clinically appropriate, <b>the first line choice of PF PGA is latanoprost 50mcg/mL.</b></li> <li>(iii) Where a PF PGA and beta-blocker combination is clinically appropriate, latanoprost 50micrograms/mL with timolol 5mg/mL eye drops (Fixapost<sup>®</sup>) is the first line choice.</li> </ul> </li> <li>• The initial prescription and supply will come from the specialist team. Prescribing can then be continued in primary care by the GP.</li> </ul>
<b>Shared Care/ Transfer of care required:</b>	N/A. Not considered necessary as other glaucoma treatments are already widely prescribed in primary care on the advice of a specialist.
<b>Cost Impact for agreed patient group</b>	<ul style="list-style-type: none"> <li>• Fixapost<sup>®</sup> drops are £3.45 cheaper per month compared to the agents delivered by separate PF drops, therefore this equates to approximately £3,300 savings per 100,000 population per annum. This would equate to savings of ~£60K per annum for SE London.</li> </ul>
<b>Usage Monitoring &amp; Impact Assessment</b>	<p><b>Acute Trusts:</b></p> <ul style="list-style-type: none"> <li>• Monitor use and submit usage data and audit reports against this recommendation and the pathway upon request to the APC.</li> </ul> <p><b>CCGs:</b></p> <ul style="list-style-type: none"> <li>• Monitor EPACK 2 data.</li> <li>• Exception reports from GPs if inappropriate prescribing requests are made to primary care.</li> </ul>
<b>Evidence reviewed</b>	<p><b>References (from evidence evaluation)</b></p> <ol style="list-style-type: none"> <li>1. Fixapost. Summary of Product Characteristics. Available online <a href="#">here</a>. (accessed 03/05/2019)</li> <li>2. Aptel F, Pfeiffer N, Schmickler S et al. Non-inferiority of preservative-free versus BAK-preserved latanoprost-timolol fixed dose combination eye drops in patients with open angle glaucoma or ocular hypertension. Journal of Glaucoma 2018 (published ahead of print)</li> </ol>

**NOTES:**

- a) Area Prescribing Committee recommendations and minutes are available publicly on the [APC website](#).
- b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.
- c) **Not to be used for commercial or marketing purposes. Strictly for use within the NHS.**